L. J. Swinnen

1.6k total citations
19 papers, 1.1k citations indexed

About

L. J. Swinnen is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, L. J. Swinnen has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pathology and Forensic Medicine and 6 papers in Genetics. Recurrent topics in L. J. Swinnen's work include Lymphoma Diagnosis and Treatment (8 papers), Viral-associated cancers and disorders (7 papers) and Polyomavirus and related diseases (5 papers). L. J. Swinnen is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Viral-associated cancers and disorders (7 papers) and Polyomavirus and related diseases (5 papers). L. J. Swinnen collaborates with scholars based in United States, Belgium and Egypt. L. J. Swinnen's co-authors include M R Costanzo, Surasak Phuphanich, Bernard F. Cole, Marc C. Chamberlain, Lawrence D. Recht, Mária Bohdalová, Günter Schumann, Michael Glantz, Kurt A. Jaeckle and Stephen B. Howell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

L. J. Swinnen

18 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. J. Swinnen United States	11	653	382	285	255	207	19	1.1k
Mary Laughlin United States	12	360 0.6×	153 0.4×	575 2.0×	142 0.6×	157 0.8×	28	1.5k
Jan Maciej Zaucha Poland	20	443 0.7×	138 0.4×	374 1.3×	428 1.7×	124 0.6×	137	1.7k
Suriya Jeyapalan United States	13	262 0.4×	263 0.7×	372 1.3×	68 0.3×	118 0.6×	33	926
María Teresa García de Dávila Argentina	23	351 0.5×	281 0.7×	225 0.8×	59 0.2×	447 2.2×	66	1.6k
C.F. LeMaistre United States	15	367 0.6×	122 0.3×	176 0.6×	230 0.9×	49 0.2×	27	829
Sarah E. Gibson United States	16	238 0.4×	94 0.2×	114 0.4×	373 1.5×	154 0.7×	40	828
Carlos Bachier United States	19	649 1.0×	120 0.3×	339 1.2×	354 1.4×	55 0.3×	86	1.5k
Madan L. Arora United States	13	460 0.7×	192 0.5×	95 0.3×	116 0.5×	297 1.4×	30	789
José C. Cruz United States	12	613 0.9×	367 1.0×	349 1.2×	125 0.5×	74 0.4×	31	1.2k
Jean Pierre Marolleau France	17	324 0.5×	77 0.2×	191 0.7×	397 1.6×	80 0.4×	53	977

Countries citing papers authored by L. J. Swinnen

Since Specialization

Citations

This map shows the geographic impact of L. J. Swinnen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. J. Swinnen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. J. Swinnen more than expected).

Fields of papers citing papers by L. J. Swinnen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. J. Swinnen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. J. Swinnen. The network helps show where L. J. Swinnen may publish in the future.

Co-authorship network of co-authors of L. J. Swinnen

This figure shows the co-authorship network connecting the top 25 collaborators of L. J. Swinnen. A scholar is included among the top collaborators of L. J. Swinnen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. J. Swinnen. L. J. Swinnen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Vos, Sven de, L. J. Swinnen, Dee Dee Wang, et al.. (2018). Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Annals of Oncology. 29(9). 1932–1938. 51 indexed citations

Zahurak, Marianna, Satish Shanbhag, L. J. Swinnen, et al.. (2017). Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients. Cancer Chemotherapy and Pharmacology. 81(2). 347–354. 4 indexed citations

Swinnen, L. J., Christopher R. Flowers, Dee Dee Wang, et al.. (2017). VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY. Hematological Oncology. 35(S2). 90–90. 4 indexed citations

Campenhout, Anja Van, et al.. (2014). Post-cryopreservation viability of mesenchymal stem cells. Cytotherapy. 16(4). S83–S83. 1 indexed citations

Nalesnik, Michael A., E. Steve Woodle, J. Michael DiMaio, et al.. (2011). Donor-Transmitted Malignancies in Organ Transplantation: Assessment of Clinical Risk. American Journal of Transplantation. 11(6). 1140–1147. 119 indexed citations

Kasamon, Yvette L., Heather A. Jacene, L. J. Swinnen, et al.. (2011). Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL).. Journal of Clinical Oncology. 29(15_suppl). 8039–8039. 1 indexed citations

Swinnen, L. J., et al.. (2009). Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). Journal of Clinical Oncology. 27(15_suppl). 2063–2063. 16 indexed citations

Bolaños‐Meade, Javier, Leo Luznik, William Matsui, et al.. (2008). Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplantation. 43(6). 477–480. 10 indexed citations

Flinn, Ian W., Brad S. Kahl, Eric C. Frey, et al.. (2006). Dose finding trial of Yttrium 90 ibritumomab tiuxetan (⁹⁰YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). Journal of Clinical Oncology. 24(18_suppl). 7535–7535. 10 indexed citations

10.

Swinnen, L. J.. (2000). Diagnosis and treatment of transplant-related lymphoma. Annals of Oncology. 11. S45–S48. 77 indexed citations

11.

Swinnen, L. J.. (2000). Post-transplant Lymphoproliferative Disorders: Implications for Acquired Immunodeficiency Syndrome-Associated Malignancies. JNCI Monographs. 2000(28). 38–43. 18 indexed citations

12.

Hsi, Eric D., Timothy P. Singleton, L. J. Swinnen, Cherie H. Dunphy, & Serhan Alkan. (2000). Mucosa-Associated Lymphoid Tissue-Type Lymphomas Occurring in Post-Transplantation Patients. The American Journal of Surgical Pathology. 24(1). 100–100. 60 indexed citations

13.

Glantz, Michael, Kurt A. Jaeckle, Marc C. Chamberlain, et al.. (1999). A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.. PubMed. 5(11). 3394–402. 390 indexed citations

14.

Swinnen, L. J.. (1997). TREATMENT OF ORGAN TRANSPLANT–RELATED LYMPHOMA. Hematology/Oncology Clinics of North America. 11(5). 963–973. 41 indexed citations

15.

Swinnen, L. J., et al.. (1995). Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 86(9). 3333–3340. 200 indexed citations

16.

Swinnen, L. J., et al.. (1994). Colonic gallstone ileus.. PubMed. 77(6). 272–4. 18 indexed citations

17.

Swinnen, L. J., M R Costanzo-Nordin, Susan G. Fisher, et al.. (1992). Increased risk of lymphoproliferative disorders following the use ofOKT3 in cardiac transplantation. 6(3). 253–259. 4 indexed citations

18.

Albain, Kathy S., et al.. (1992). Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience.. PubMed. 19(3 Suppl 9). 102–9. 9 indexed citations

19.

Swinnen, L. J., et al.. (1989). 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.. PubMed. 49(6). 1383–9. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact